Last 12 months
Inside the activity.
2 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 1 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 7,096 | $20.67 | $146,674.32 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,080 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 2,957 | $20.67 | $61,121.19 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,176 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 15,493 | $20.67 | $320,240.31 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,133 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 30,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 5,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 22:40 UTC |
Ribeiro RamiroChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002119 · primarydocument.xml · derivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at March 1st, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:46 UTC |
Duker Jay S.Director · President and CEO
|
GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001895 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 22,500 F1 · kind: On February 27, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. F2 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:46 UTC |
Duker Jay S.Director · President and CEO
|
GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001895 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,420 F1 · kind: On February 27, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC |
Duker Jay S.Director · President and CEO
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001624 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 20,000 F1 · kind: On February 20, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. F2 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC |
Duker Jay S.Director · President and CEO
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001624 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,920 F1 · kind: On February 20, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 14 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 115,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 13 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftStock Option (Right to Buy) · Derivative | 4,452 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 12 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 155,822 Underlying: Common Stock · 4,452 shares Expires 2031-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F8 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftStock Option (Right to Buy) · Derivative | 4,452 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 11 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,878 Underlying: Common Stock · 4,452 shares Expires 2031-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F8 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftStock Option (Right to Buy) · Derivative | 3,116 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 10 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 73,242 Underlying: Common Stock · 3,116 shares Expires 2030-02-28 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 28, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftStock Option (Right to Buy) · Derivative | 3,116 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 9 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 3,116 shares Expires 2030-02-28 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 28, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftCommon Stock | 74,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 6 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 126,889 F2 · kind: On February 13, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GiftCommon Stock | 74,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,351 F2 · kind: On February 13, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 17:38 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001292 · primarydocument.xml · derivative · entry 6 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 17:38 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,967 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001292 · primarydocument.xml · derivative · entry 5 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,967 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 17:38 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Tax withholdingCommon Stock | 1,701 | $28.80 | $48,988.80 |
DisclosureSEC source: 0001562180-24-001292 · primarydocument.xml · nonDerivative · entry 4 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,916 F2 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 17:38 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Tax withholdingCommon Stock | 1,955 | $28.80 | $56,304.00 |
DisclosureSEC source: 0001562180-24-001292 · primarydocument.xml · nonDerivative · entry 3 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,617 F2 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 17:38 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001292 · primarydocument.xml · nonDerivative · entry 2 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 17:38 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001292 · primarydocument.xml · nonDerivative · entry 1 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 643 shares acquired on January 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Exercise / conversionRestricted Stock Units · Derivative | 17,534 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,534 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Tax withholdingCommon Stock | 6,981 | $28.80 | $201,052.80 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,032 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Tax withholdingCommon Stock | 7,962 | $28.80 | $229,305.60 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,013 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Exercise / conversionCommon Stock | 17,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:38 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001291 · primarydocument.xml · derivative · entry 6 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,833 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:38 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,967 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001291 · primarydocument.xml · derivative · entry 5 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,967 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:38 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 1,458 | $28.80 | $41,990.40 |
DisclosureSEC source: 0001562180-24-001291 · primarydocument.xml · nonDerivative · entry 4 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,607 F2 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:38 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 1,734 | $28.80 | $49,939.20 |
DisclosureSEC source: 0001562180-24-001291 · primarydocument.xml · nonDerivative · entry 3 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,065 F2 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:38 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 5,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001291 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:38 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001291 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 691 shares acquired on January 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · derivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,833 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,967 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · derivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,967 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 2,565 | $28.80 | $73,872.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,222 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 2,518 | $28.80 | $72,518.40 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,787 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 5,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:37 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 7,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001290 · primarydocument.xml · derivative · entry 6 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:37 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,967 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001290 · primarydocument.xml · derivative · entry 5 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,967 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:37 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 1,458 | $28.80 | $41,990.40 |
DisclosureSEC source: 0001562180-24-001290 · primarydocument.xml · nonDerivative · entry 4 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,920 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:37 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 2,075 | $28.80 | $59,760.00 |
DisclosureSEC source: 0001562180-24-001290 · primarydocument.xml · nonDerivative · entry 3 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,378 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:37 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001290 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:37 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001290 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 17:15 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 209 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001562180-24-001050 · primarydocument.xml · derivative · entry 3 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,375 Underlying: Common Stock · 209 shares Expires 2031-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.